Epilepsy is a common co-occurring condition in older adults with Down syndrome and frequently associated with the emergence of Alzheimer's disease-related cognitive decline.1 Likely to be under-recognised and often untreated in the earlier stages, late-onset myoclonic epilepsy in Down syndrome (LOMEDS) presents as myoclonic or tonic–clonic seizures and can be both a manifestation of underlying Alzheimer's disease pathology and an accelerator of disease progression.2 How seizure onset timing in adults with Down syndrome relates to Alzheimer's disease symptoms and progression remains unclear, complicating interpretation of decline and clinical management.
Kaynak: The Lancet
